Vivos Therapeutics (VVOS) investor relations material

Company overview and business model

• Medical technology and services company offering proprietary oral appliances and treatments for obstructive sleep apnea (OSA) and related disorders in adults and children.

• Historically focused on training dentists, now pivoting to strategic alliances and acquisitions of sleep centers and specialty providers, with a profit-sharing model.

• Acquired The Sleep Center of Nevada in June 2025, integrating diagnostic and treatment services to capture higher-margin revenue streams.

• Developing a revised management model for collaborations with sleep centers not interested in outright sale, using co-owned management entities.

Financial performance and metrics

• SCN integration yielded $2.2 million in diagnostic revenue and $1.3 million in treatment revenue in Q3 2025, with high demand exceeding current capacity.

• Each Sleep Optimization (SO) team could potentially generate over $500,000 in monthly collections with contribution margins above 50%.

Use of proceeds and capital allocation

• No proceeds from resale of shares by the selling stockholder; company may receive up to $8.3 million from warrant exercises, to be used for general corporate purposes and working capital.

• Proceeds from recent financings and warrant exercises are funding integration activities and operational expansion.